Wandercraft’s ‘Walk in New York’ Clinic Opens for Hands-Free Exoskeleton Therapy

French robotics innovator Wandercraft, a Cure resident company, has inaugurated its first U.S. clinic, "Walk in New York," at 345 Park Avenue South in Manhattan. The facility offers patients with mobility impairments a range of advanced services using the company's Atalante X, a self-balancing, hands-free exoskeleton designed to mimic the way a person naturally walks.

“Our mission has always been to restore everyday mobility, building hand-in-hand with the community of people we serve,” said Matthieu Masselin, CEO of Wandercraft. “Walk in New York is a space where innovation meets the real world. The team now has the powerful opportunity to work alongside our users, meet their families, hear their stories, and become an active participant in their mobility journey inside and outside of the device.”

The new clinic is the result of a collaboration between Wandercraft and licensed physical therapists. They designed the facility to be “a space where walking is more than a goal, it's a transformative experience accessible to all, regardless of trunk or upper extremity strength.”

“Wandercraft’s breakthrough work reflects the kind of transformative innovation Cure was built to nurture,” said Seema Kumar, CEO of Cure. “We are proud to support this vital endeavor. Walk in New York is about more than clinical care – it’s about building real connection and fostering community between our ecosystem and the patients they serve. It exemplifies Cure’s mission to advance health by empowering entrepreneurs to turn bold ideas into real-world impact.”

Immersive Program Helps People with Neurological Conditions Improve Mobility

The clinic’s immersive program offers people with spinal cord injuries (SCI), stroke, and other neurological conditions personalized screenings, tailored therapy programs using Atalante X and progress tracking. The clinic provides rehabiliation for patients with traumatic brain injury, multiple sclerosis, cerebral palsy, Parkinson's disease, vestibular disorders, concussion or balance disorders.

Wandercraft's clinic also will leverage virtual reality systems that provide real-time feedback, mirror therapy to aid motor function recovery and advanced gait analysis. The clinic's offer of rehabilitation innovations include such as Intensive Virtual Stimulation by Dessintey and a Virtual Reality Treadmill by ezyGain.

The clinic’s website notes it accepts major insurance providers including Aetna, Cigna, Medicare, BlueCross BlueShield, Humana and United Healthcare.

Wandercraft reported that the clinic is a milestone in its ongoing mission to use robotics technology to make everyday mobility accessible to everyone. Also, the company stated that the clinic “will serve as the hub where individuals can receive their personal devices, undergo comprehensive training, and access ongoing support."

Wandercraft’s Award-Winning Exoskeleton Technology

Wandercraft is a pioneer in exoskeleton technology. It received international recognition as a finalist for a 2025 SXSW Innovation Award, and NVIDIA featured the company as a key member of its ecosystem at CES 2025.

"Walk in New York" is set to become the central hub for Wandercraft's forthcoming Personal Exoskeleton, intended for everyday home use by individuals seeking greater mobility independence.

Unlike traditional exoskeletons, Wandercraft’s Personal Exoskeleton is designed to adapt in real time to a user’s movements and environment to enable smooth walking across varied surfaces, such as carpet, concrete, and tile. Sensors embedded in the machine detect the different movements in the user’s body, which prompts the machine’s AI-powered response and movement. The exoskeleton’s self-balancing design also lets users to walk without the need for crutches or walkers, letting their hands remain free.

Wandercraft has an ongoing clinical trial to assess the safety and efficacy of its Personal Exoskeleton in people with living with high-level SCI, defined as a complete or an incomplete SCI at or above the T6 vertebrae in the upper-middle spine.